01. December 2011
Zedira's Transglutaminase Newsletter December 2011 - transglutaminase specialty reagents catalog

25. November 2011
Presse-Mitteilung: Zedira lizensiert ZED-101 zur medikamentösen Behandlung der Zöliakie in Europa an Dr. Falk Pharma

02. September 2011
Zedira presents data dealing with the production and characterization of rFactor XIII in September 2011

01. September 2011
Transglutaminase Newsletter September 2011 - All you need for enzymatic labeling!

09. August 2011
Transglutaminase Newsletter August 2011 - Facebook & Twitter

10. July 2011
Novel Product: DGPx1 (Deamidated Gliadin Peptide fused to a carrier protein)

05. July 2011
Congratulations to Ethel Kautto for winning the iPadTM!

02. July 2011
Transglutaminase Newsletter July 2011 Superior performance of Open tTG™-ELISA presented at ICDS 2011 in Oslo

17. June 2011
Zedira presents preclinical data at "14th International Coeliac Disease Symposium 2011" in Oslo

08. June 2011
Meet Zedira at icds 14th International Coeliac Disease Symposium 2011

03. June 2011
BMBF supports development of FXIIIa blocker for thromboprophylaxis - June 2011

04. April 2011
Transglutaminase Newsletter April 2011 Open conformation TG2-ELISA-Kits – endotoxin free TG2

02. February 2011
Transglutaminase Newsletter February 2011 Drug Discovery Platform – Fluorescent Transglutaminase Antibodies

20. January 2011
EyeSense names Zedira as supplier for diagnostic products – January 2011


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA